Compare Stocks → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CRBPNASDAQ:GERNNASDAQ:NEPTNASDAQ:PTGXNASDAQ:UROV Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBPCorbus Pharmaceuticals$39.71+8.7%$34.93$3.03▼$49.87$417.35M2.46807,173 shs209,871 shsGERNGeron$3.70-0.8%$2.71$1.64▼$4.05$2.02B0.6211.20 million shs5.50 million shsNEPTNeptune Wellness Solutions$0.39$0.19▼$28.00$906K2.19462,687 shs2.25 million shsPTGXProtagonist Therapeutics$25.48+1.0%$28.54$13.72▼$33.34$1.48B2.01708,724 shs283,788 shsUROVUrovant Sciences$16.24$16.23$7.15▼$16.26$531.75M2.36114,469 shsN/AThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBPCorbus Pharmaceuticals-1.70%-8.68%-14.57%+418.16%+262.76%GERNGeron+1.36%-1.06%+14.42%+97.35%+49.80%NEPTNeptune Wellness Solutions0.00%0.00%0.00%-59.18%-99.22%PTGXProtagonist Therapeutics-1.37%-8.82%-12.49%+1.82%+7.50%UROVUrovant Sciences0.00%0.00%0.00%0.00%0.00%Strange new buyer driving up gold (Ad)One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."But there's a much better move you can make to get in front of these big moves today.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRBPCorbus Pharmaceuticals4.4476 of 5 stars3.53.00.04.72.83.30.6GERNGeron3.2097 of 5 stars3.53.00.01.31.41.70.6NEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/AN/AN/AN/APTGXProtagonist Therapeutics1.5053 of 5 stars3.51.00.00.02.72.50.0UROVUrovant SciencesN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRBPCorbus Pharmaceuticals3.00Buy$52.0030.95% UpsideGERNGeron3.00Buy$5.3344.14% UpsideNEPTNeptune Wellness SolutionsN/AN/AN/AN/APTGXProtagonist Therapeutics3.00Buy$36.0041.29% UpsideUROVUrovant SciencesN/AN/AN/AN/ACurrent Analyst RatingsLatest GERN, CRBP, PTGX, NEPT, and UROV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2024GERNGeronNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.004/10/2024GERNGeronWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$6.003/15/2024GERNGeronWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$6.003/15/2024GERNGeronThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.003/15/2024GERNGeronNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.003/13/2024CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$51.00 ➝ $58.003/6/2024CRBPCorbus PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$4.00 ➝ $46.002/28/2024GERNGeronNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.002/28/2024PTGXProtagonist TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$34.00 ➝ $37.002/28/2024PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.001/29/2024CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$20.00 ➝ $51.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRBPCorbus Pharmaceuticals$880K474.26N/AN/A($1.56) per share-25.46GERNGeron$237K8,537.70N/AN/A$0.46 per share8.04NEPTNeptune Wellness Solutions$52.62M0.00N/AN/A($91.90) per share0.00PTGXProtagonist Therapeutics$60M24.75N/AN/A$5.84 per share4.36UROVUrovant SciencesN/AN/AN/AN/A($1.90) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRBPCorbus Pharmaceuticals-$44.60M-$10.37N/AN/AN/AN/A-920.31%-111.56%5/14/2024 (Estimated)GERNGeron-$184.13M-$0.33N/AN/AN/A-77,691.14%-63.33%-44.71%5/9/2024 (Estimated)NEPTNeptune Wellness Solutions-$60.46M-$106.72N/AN/AN/A-128.13%N/A-141.94%7/15/2024 (Estimated)PTGXProtagonist Therapeutics-$78.96M-$1.49N/AN/AN/AN/A-27.49%-25.30%5/2/2024 (Estimated)UROVUrovant Sciences-$146.74M-$4.71N/AN/AN/AN/AN/A-162.90%N/ALatest GERN, CRBP, PTGX, NEPT, and UROV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/12/2024Q4 2023CRBPCorbus Pharmaceuticals-$2.36-$1.81+$0.55-$1.81N/AN/A2/28/2024Q4 23GERNGeron-$0.10-$0.09+$0.01-$0.09$0.06 million$0.02 million 2/27/202412/31/2023PTGXProtagonist Therapeutics$0.05$0.44+$0.39$0.44$60.00 million$60.00 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/AGERNGeronN/AN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/AUROVUrovant SciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRBPCorbus PharmaceuticalsN/A0.740.74GERNGeron0.143.163.16NEPTNeptune Wellness SolutionsN/A0.230.10PTGXProtagonist TherapeuticsN/A16.7116.71UROVUrovant SciencesN/A2.912.91OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRBPCorbus Pharmaceuticals64.64%GERNGeron73.71%NEPTNeptune Wellness Solutions14.44%PTGXProtagonist Therapeutics98.63%UROVUrovant Sciences18.44%Insider OwnershipCompanyInsider OwnershipCRBPCorbus Pharmaceuticals4.00%GERNGeron3.10%NEPTNeptune Wellness Solutions5.10%PTGXProtagonist Therapeutics5.00%UROVUrovant Sciences2.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCRBPCorbus Pharmaceuticals1910.51 million10.09 millionOptionableGERNGeron141546.87 million529.92 millionOptionableNEPTNeptune Wellness Solutions584.53 million4.30 millionNot OptionablePTGXProtagonist Therapeutics11258.28 million55.36 millionOptionableUROVUrovant Sciences7032.74 millionN/ANot OptionableGERN, CRBP, PTGX, NEPT, and UROV HeadlinesSourceHeadlineA2 Bio’s new CEO aims to grow platformpacbiztimes.com - April 8 at 6:15 AMC-Suite Shuffle: A2 Bio, Bayer, BioNTech and Morebiospace.com - March 27 at 2:46 AMA2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of Directorsfinance.yahoo.com - March 26 at 3:06 AMHEALTH BEHAVIOR AND NUTRITION SCIENCESudel.edu - February 17 at 2:30 PMBulletin Science and Security Boardthebulletin.org - February 15 at 3:32 PMSecretary-General’s Guidance Note on Behavioural Scienceun.org - February 5 at 9:35 AMMarine Sciences & Technologyuml.edu - January 7 at 12:52 PMThe 7 Best Science Kits for Kids and Teenspopularmechanics.com - December 22 at 12:32 AMCareers in Computer Sciencemccormick.northwestern.edu - December 11 at 10:18 AMPhD in Information Sciencedrexel.edu - December 8 at 10:01 AMPetauri™ Elects William Fleming and James Robinson to Its Board of Directorsfinance.yahoo.com - December 6 at 10:09 AMCore Requirements & Coursesbc.edu - December 1 at 1:25 PMInspiring Women in Sciencenature.com - November 28 at 10:11 AMDevelop your own cognitive toolkit.miamioh.edu - November 17 at 9:55 AMBenign Prostatic Hyperplasia Market Size in 7MM is expected to witness a major change in the study period 2019–2032, estimates DelveInsightmedgadget.com - November 16 at 8:17 AMPM360 Announces 2023 Trailblazer Award Winnersfinance.yahoo.com - October 4 at 8:59 AMHeavy Drinking Not Tied to Lower Response to DAAs for Hepatitis Cmedpagetoday.com - September 26 at 3:23 PMEledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directorsfinance.yahoo.com - September 11 at 8:30 AMClinical and Translational Science Institutebuffalo.edu - September 8 at 9:36 PMMDxHealth CEO Bullish After Q2 Revenue Boostocbj.com - September 5 at 8:49 PMWindmill Model Science Projecteducation.com - August 15 at 1:51 AMTop Science Newssciencedaily.com - August 10 at 1:52 PMAbout This Sitesciencedaily.com - August 5 at 4:13 PMCNVCF - BioHarvest Sciences Inc.finance.yahoo.com - July 31 at 2:30 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCorbus PharmaceuticalsNASDAQ:CRBPCorbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.GeronNASDAQ:GERNGeron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Neptune Wellness SolutionsNASDAQ:NEPTNeptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada. Protagonist TherapeuticsNASDAQ:PTGXProtagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Urovant SciencesNASDAQ:UROVUrovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.